Pacific Biosciences of California, Inc. (PACB)

Market Cap	378.27M
Revenue (ttm)	154.01M
Net Income (ttm)	-309.85M
Shares Out	297.85M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,840,174
Open	1.320
Previous Close	1.320
Day's Range	1.250 - 1.350
52-Week Range	1.080 - 2.720
Beta	2.03
Analysts	Buy
Price Target	2.46 (+93.7%)
Earnings Date	May 8, 2025

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 27, 2010
• Employees: 575
• Stock Exchange: NASDAQ
• Ticker Symbol: PACB
• Website: https://www.pacb.com

Financial Performance

In 2024, PACB's revenue was $154.01 million, a decrease of -23.19% compared to the previous year's $200.52 million. Losses were -$309.85 million, 1.02% more than in 2023.

Analyst Forecast

According to 13 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is $2.46, which is an increase of 93.70% from the latest price.

Price Target

$2.46

(93.70% upside)

Analyst Consensus: Buy